Abstract
Substantial progress has been made in the last years in characterizing the susceptibility genes involved in IBD pathogenesis, especially for Crohns disease. Although some genetic factors associated with Crohn's disease also predispose individuals to ulcerative colitis, markers specific only for ulcerative colitis have been found. Recent genomewide association studies in ulcerative colitis have identified several new loci, and suggested many new potential pathways. The identified susceptibility genes and their variants could be useful to predict disease course and to improve stratification of patients, when correlated with other subphenotypes. Moreover, understanding the biological pathways involved in the disease could lead to the development of new treatments and molecules that specifically target such pathways, discover different therapeutic approaches and eventually progress to personalized treatment.
Keywords: Crohn's disease, genome-wide association studies, Inflammatory bowel disease, single nucleotide polymorphism, therapy, ulcerative colitis, IRGM, IL23R, IL12B, NKX2-3
Current Drug Targets
Title: Genetics and Ulcerative Colitis: What are the Clinical Implications?
Volume: 12 Issue: 10
Author(s): Anna Latiano and Vito Annese
Affiliation:
Keywords: Crohn's disease, genome-wide association studies, Inflammatory bowel disease, single nucleotide polymorphism, therapy, ulcerative colitis, IRGM, IL23R, IL12B, NKX2-3
Abstract: Substantial progress has been made in the last years in characterizing the susceptibility genes involved in IBD pathogenesis, especially for Crohns disease. Although some genetic factors associated with Crohn's disease also predispose individuals to ulcerative colitis, markers specific only for ulcerative colitis have been found. Recent genomewide association studies in ulcerative colitis have identified several new loci, and suggested many new potential pathways. The identified susceptibility genes and their variants could be useful to predict disease course and to improve stratification of patients, when correlated with other subphenotypes. Moreover, understanding the biological pathways involved in the disease could lead to the development of new treatments and molecules that specifically target such pathways, discover different therapeutic approaches and eventually progress to personalized treatment.
Export Options
About this article
Cite this article as:
Latiano Anna and Annese Vito, Genetics and Ulcerative Colitis: What are the Clinical Implications?, Current Drug Targets 2011; 12 (10) . https://dx.doi.org/10.2174/138945011796818171
DOI https://dx.doi.org/10.2174/138945011796818171 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular and Cellular Regulators of Cancer Angiogenesis
Current Cancer Drug Targets CD24, A Review of its Role in Tumor Diagnosis, Progression and Therapy
Current Gene Therapy Quality Survival with Fertility after Gynaecological and other Cancers
Current Women`s Health Reviews Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy
Current Cancer Drug Targets Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules
Current Medicinal Chemistry Foods for Health and to Treat Diseases
Current Pediatric Reviews Thymidylate Synthase Gene in Pharmacogenetics
Current Pharmacogenomics Human Mesenchymal Stem Cells (hMSCs) as Targets of DNA Damaging Agents in Cancer Therapy
Current Cancer Drug Targets Mechanisms for the Inhibition of Colon Cancer Cells by Sulforaphane through Epigenetic Modulation of MicroRNA-21 and Human Telomerase Reverse Transcriptase (hTERT) Down-regulation
Current Cancer Drug Targets Pharmacogenetics of Phase I and Phase II Drug Metabolism
Current Pharmaceutical Design Fluorescence Polarization Immunoassays for Metal Ions
Combinatorial Chemistry & High Throughput Screening The Urokinase Receptor in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Is Metformin a Therapeutic Paradigm for Colorectal Cancer: Insight into the Molecular Pathway?
Current Drug Targets Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement
Current Medicinal Chemistry Improving Cancer Chemotherapy with Modulators of ABC Drug Transporters
Current Drug Targets Sulfotransferase 1A1 as a Biomarker for Susceptibility to Carcinogenesis: From Molecular Genetics to the Role of Dietary Flavonoids
Current Drug Metabolism Clinical Strategies for the Blockade of IL-18 in Inflammatory Bowel Diseases
Current Drug Targets Microemulsions for Colorectal Cancer Treatments. General Considerations and Formulation of Methotrexate
Mini-Reviews in Medicinal Chemistry Study of Parasitic Infections, Cancer, and other Diseases with Mass-Spectrometry and Quantitative Proteome-Disease Relationships
Current Proteomics Pharmacogenetics of Irinotecan Disposition and Toxicity: A Review
Current Clinical Pharmacology